Pharmacopeia

CWP-0179

Nifedipine

Cardiovascular · Level 3 Obstetric & Reproductive · Level 3

Core pharmacology

Main Action

-Inhibition of L-type calcium channels leads to decreases myometrial SM → decreased SM contraction

Presentation

available in sustained and immediate release oral formulations, 10-60mg

Mechanism of action

Selectively dilates arterial resistance vessels. The ↓in arterial BP elicits sympathetic reflexes, with resulting tachycardia and positive inotropy.

Physiological effects

Thus, arteriolar resistance and blood pressure are lowered, contractility and segmental ventricular function are improved, and heart rate and cardiac output are modestly increased.

Distribution

lipid solubility moderately low, minimal BBB

Protein binding

~90%

Volume of distribution

0.62-1.12 L/kg

Metabolism

Hepatic via CYP3A4 to inactive metabolites

Excretion

Urine (60% to 80% as inactive metabolites); faeces

Half-life

2-5 hours (↑ in liver failure)

Route And Dose

PO 10-20mg BD.

Class Group

Dihydropyridine calcium-channel blocker and arterial vasodilator.

Indications Uses

Used for angina, hypertension including pregnancy-associated hypertension, Raynaud phenomenon and coronary arterial spasm.

Absorption

Completely absorbed after oral administration, with oral bioavailability approximately 45-68% because of first-pass metabolism.

Introduction

prototypical dihydropyridine calcium channel blocker

Adverse Effects Toxicity

Common adverse effects are headache, flushing and dizziness from vasodilatation. Peripheral oedema, eye pain and gingival hyperplasia are also reported. Abrupt withdrawal after chronic therapy may cause rebound hypertension.